Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron.
dl-threo-Methylphenidate (Ritalin) was labeled with carbon-11 (t1/2:20.4 minutes) in order to measure its pharmacokinetics, to evaluate it as a radiotracer for the presynaptic dopaminergic neuron, and to examine its sensitivity to the loss of dopaminergic neurons. Positron emission tomographic (PET) studies were carried out in the baboon to determine specificity for the presynaptic dopaminergic neuron and in humans to assess sensitivity to neuronal loss. Studies with [11C]dl-threo-methylphenidate ([11C]MP) in baboon demonstrated high regional uptake in the striatum. Peak uptake (0.04%/cc) occurred at 5-15 minutes post-injection. The half-time for clearance from peak uptake for [11C]MP was 60 minutes and the ratio between the radioactivity in the striatum and that in the cerebellum (ST/CB) ranged from 2.2 to 2.6 at 40 minutes. Repeated measures in the same baboon showed < or = 8% variability in the ST/CB ratio. Pretreatment with unlabeled methylphenidate (0.5 mg/kg) or GBR12909 (1.5 mg/kg) 30 minutes prior to [11C]MP injection markedly reduced the striatal but not the cerebellar uptake of [11C]MP, demonstrating the saturable and specific binding of [11C]MP to a site on the dopamine transporter in the brain. In both cases, the ratio of striatum to cerebellum (ST/CB) after pretreatment was reduced by about 43%. The ratios of distribution volumes at the steady-state for the striatum to cerebellum (ST/CB) for these two separate studies in the same baboon were reduced by 37 and 38%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Ding
Y S
YS
Brookhaven National Laboratory, Upton, New York 11973.
Fowler
J S
JS
Volkow
N D
ND
Gatley
S J
SJ
Logan
J
J
Dewey
S L
SL
Alexoff
D
D
Fazzini
E
E
Wolf
A P
AP
D000368:Aged; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004298:Dopamine / Q000502:physiology*; D018765:Dopamine Uptake Inhibitors / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008297:Male; D008774:Methylphenidate / Q000493:pharmacokinetics* / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D010215:Papio; D010300:Parkinson Disease / Q000378:metabolism; D010879:Piperazines / Q000493:pharmacokinetics; D017661:Receptors, Presynaptic / Q000187:drug effects*; D014055:Tomography, Emission-Computed
D018765:Dopamine Uptake Inhibitors; D010879:Piperazines; D017661:Receptors, Presynaptic; D008774:Methylphenidate; C043425:vanoxerine; D004298:Dopamine